middle.news
Dimerix Confirms ACTION3 Trial Powered to Show DMX-200 Proteinuria Benefit
9:44am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Dimerix Confirms ACTION3 Trial Powered to Show DMX-200 Proteinuria Benefit
9:44am on Tuesday 28th of April, 2026 AEST
Key Points
Blinded review confirms >90% power for proteinuria endpoint
Adult cohort fully recruited; pediatric recruitment ongoing
FDA endorses proteinuria for full regulatory approval
Decision to avoid accelerated approval reduces trial risks
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE